肝癌患者术后肝动脉化疗栓塞联合胸腺肽治疗预防复发的随机对照研究

Transcatheter hepatic arterial chemoembolization and thymosin α_1 in postoperative treatment of hepatocellular carcinoma

目的 随机对照观察肝癌患者术后肝动脉化疗栓塞 (TACE)联合胸腺肽α1(Tα1)治疗对预防肝细胞癌复发的影响。方法 5 7例肝细胞癌患者随机分为 3组 :手术 +TACE +Tα1组 (A组 ) 18例 ,手术 +TACE组 (B组 ) 2 3例和手术切除组 (C组 ) 16例。观察患者术后肿瘤复发率、复发时间和生存期。结果 A、B、C组 1年复发率分别为 83.3%、87.0 %和 87.5 % (P =0 .92 6 ) ,中位复发时间分别为7.0个月、5 .0个月和 4 .0个月 (P =0 .0 39) ,中位生存期分别为 10 .0个月、7.0个月和 8.0个月 (P =0 .0 0 2 )。结论 术后TACE +Tα1治疗不能降低肝细胞癌患者术后复发率 ,但可延缓复发时间 ,提高生存期。

Objective To observe the effect of postoperative transcatheter hepatic arterial chemoembolization (TACE) and thymosin α 1 (T α1) treatment on recurrence of hepatocellular carcinoma(HCC). Methods From Jan 2000 to Dec 2002, 57 patients with HCC were randomly divided into three groups: group A (n=18) received hepatectomy plus postoperative TACE and T α1, group B(n=23) received hepatectomy plus postoperative TACE and group C (n=16) received hepatectomy only. The recurrence rate, the time to tumor recurrence and the median survival for the three groups were investigated. Results For group A, B and C, the 1 year recurrence rate was 83.3%, 87.0% and 87.5% (P=0.926), respectively. The time to tumor recurrence was 7.0, 5.0 and 4.0 months (P=0.039), respectively. The median survival was 10.0, 7.0 and 8.0 months (P=0.002), respectively. Conclusion Postoperative TACE plus Tα 1 treatment for HCC patients does not decrease the recurrence rate but may delay its occurrence and prolong surviving time.